Stem cells: Cell therapy for cardiac repair: what is needed to move forward?

Nature Reviews Cardiology

Volumn 14, Issue 5, 2017, Pages 257-258

  Bolli, Roberto ^a   Ghafghazi, Shahab ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; CELL DIFFERENTIATION; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; HEART; HEART FAILURE; HEART FUNCTION; HUMAN; NONHUMAN; PATIENT SAFETY; RISK ASSESSMENT; SHORT SURVEY; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TISSUE REPAIR; AUTOTRANSPLANTATION; HEART INFARCTION; NEEDS ASSESSMENT; PATHOPHYSIOLOGY; PROCEDURES;

HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; NEEDS ASSESSMENT; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 85016553734     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2017.38     Document Type: Short Survey

References (10)

1. Mathur, A., et al. The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/.ehw640 (2017).
2. Keith, M. C., & Bolli, R. "String theory" of c kitpos cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. Circ. Res. 116, 1216-1230 (2015).
3. Gyongyosi, M., et al. Meta-Analysis of cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ. Res. 116, 1346-1360 (2015).
4. Fisher, S. A., Doree, C., Mathur, A., Taggart, D. P., & Martin-Rendon, E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst. Rev. 12, CD007888 (2016).
5. Khan, A. R., et al. Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: a systematic review and meta-Analysis. Circ. Res. 118, 984-993 (2016).
6. Bolli, R. Repeated cell therapy: a paradigm shift whose time has come. Circ. Res. http://dx.doi.org/10.1161/.CIRCRESAHA.117.310710 (2017).
7. Guo, Y., et al. Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction. Basic Res. Cardiol. 112, 18 (2017).
8. Tokita, Y., et al. Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration: a new paradigm in cell therapy. Circ. Res. 119, 635-651 (2016).
9. Jones, S. P., et al. The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ. Res. 116, 572-586 (2015).
10. Bolli, R., & Ghafghazi, S. Cell therapy needs rigorous translational studies in large animal models. J. Am. Coll. Cardiol. 66, 2000-2004 (2015).